MELATONIN-MEDIATED CARDIOPROTECTION ACROSS EXPERIMENTAL MODELS OF CARDIAC INJURY: A CRITICAL NARRATIVE REVIEW WITH PRIMARY-SOURCE QUANTITATIVE COMPARISONS

Authors

  • Rubens Barbosa Rezende Author

Keywords:

melatonin; cardioprotection; doxorubicin; ischemia/reperfusion; oxidative stress; mitochondria; inflammation; narrative review; primary-source verification; ratio of means

Abstract

Background: Experimental studies have reported cardioprotective effects of melatonin across ischemic, toxic, metabolic, inflammatory and hemodynamic forms of cardiac injury, but neither the magnitude nor the biological basis of protection is likely to be uniform across etiologies. Methods: We conducted a structured critical narrative review centered on primary-source verification. Candidate studies were identified through targeted, iterative literature searches and citation tracking rather than through a prospectively registered exhaustive search workflow. Controlled in vivo mammalian comparisons of melatonin versus an appropriate injury control formed the quantitative core, while in vitro experiments were used for mechanistic interpretation. Numerical contrasts were retained only after verification of group identity, sample size, central estimate, dispersion, unit or scale, and time point in the primary source. Ratio of means (RoM) with 95% confidence intervals was used as a descriptive study-level effect measure for positive continuous outcomes when biologically appropriate. Repeated measurements, shared controls and potentially overlapping cohorts were not treated as independent. Results: Primary-source-verified comparisons showed a broadly protective direction but substantial between-model variation. In anthracycline injury, corrected data from Pehlivan et al. showed lower CK-MB (RoM 0.543, 95% CI 0.408–0.722), MDA (0.564, 0.364–0.872) and IL-6 (0.301, 0.209–0.432) with melatonin. Othman et al. showed lower CK-MB (0.458, 0.430–0.488) and cardiac TBARS (0.618, 0.590–0.647) with higher cardiac GSH (2.265, 2.167–2.367), while Liu et al. (2018) provided a quantitative reduction in myocardial apoptosis (0.354, 0.273–0.459) together with perturbation-supported AMPK/PGC-1α evidence. In myocardial ischemia/reperfusion, infarct size was lower with melatonin (0.674, 0.609–0.746); isoproterenol injury showed lower cTnT (0.504, 0.441–0.576); and endotoxemia showed lower CK-MB (0.547, 0.437–0.685) and TBARS (0.474, 0.384–0.586). In diabetic rats with recovered individual-level supplementary data, 4-HNE, troponin-T, CK-MB and LDH were lower, whereas GSH and GPx were higher. Raw cardiopulmonary bypass data similarly showed lower CK-MB, MDA and IL-6 and higher SOD at T2, while echocardiographic effects remained imprecise. A trastuzumab model broadened the cancer-therapy evidence but remained qualitative because exact endpoint-level group statistics were not tabulated. Perturbation experiments supported model-specific roles for PER2, AMPK/PGC-1α, YAP/ACSL4, SIRT1/Nrf2, endothelial LRRC8A–AKT/eNOS/HIF-1α and MT2/SIRT1/Nrf2. A small randomized human trial was considered separately as translational context and was not combined with animal comparisons. Conclusions: Melatonin-associated cardioprotection is directionally reproducible across several experimental etiologies, but the evidence does not support a single universal effect size or mechanism. The most defensible interpretation is a model-dependent protective phenotype involving redox control, mitochondrial preservation, inflammatory modulation and regulated cell death pathways, with timing, dose, route and cardiac compartment as plausible effect modifiers.

References

Abdulwahab DA, El-Missiry MA, Shabana S, Othman AI, Amer ME. Melatonin protects the heart and pancreas by improving glucose homeostasis, oxidative stress, inflammation and apoptosis in T2DM-induced rats. Heliyon. 2021;7(3):e06474. doi:10.1016/j.heliyon.2021.e06474.

Acikel M, Buyukokuroglu ME, Aksoy H, Erdogan F, Erol MK. Protective effects of melatonin against myocardial injury induced by isoproterenol in rats. J Pineal Res. 2003;35(2):75–79. doi:10.1034/j.1600-079X.2003.00056.x.

Agapito MT, Antolín Y, del Brío MT, López-Burillo S, Pablos MI, Recio JM. Protective effect of melatonin against adriamycin toxicity in the rat. J Pineal Res. 2001;31(1):23–30. doi:10.1034/j.1600-079X.2001.310104.x.

Arinno A, Maneechote C, Khuanjing T, et al. Cardioprotective effects of melatonin and metformin against doxorubicin-induced cardiotoxicity in rats are through preserving mitochondrial function and dynamics. Biochem Pharmacol. 2021;192:114743. doi:10.1016/j.bcp.2021.114743. Corrigendum: Biochem Pharmacol. 2023;208:115414. doi:10.1016/j.bcp.2023.115414.

Arinno A, Maneechote C, Khuanjing T, et al. Melatonin and metformin ameliorated trastuzumab-induced cardiotoxicity through the modulation of mitochondrial function and dynamics without reducing its anticancer efficacy. BBA Mol Basis Dis. 2023;1869:166618. doi:10.1016/j.bbadis.2022.166618.

Aygun H, Gul SS. Cardioprotective effect of melatonin and agomelatine on doxorubicin-induced cardiotoxicity in a rat model: an electrocardiographic, scintigraphic and biochemical study. Bratisl Lek Listy. 2019;120(4):249–255. doi:10.4149/BLL_2019_045.

Balli E, Mete UO, Tuli A, Tap O, Kaya M. Effect of melatonin on the cardiotoxicity of doxorubicin. Histol Histopathol. 2004;19(4):1101–1108. doi:10.14670/HH-19.1101.

Bilginoğlu A, Aydin D, Özsoy S, Aygün H. Protective effect of melatonin on adriamycin-induced cardiotoxicity in rats. Turk Kardiyol Dern Ars. 2014;42(3):265–273. doi:10.5543/tkda.2014.36089.

Di W, Jin Z, Lei W, et al. Protection of melatonin treatment and combination with traditional antibiotics against septic myocardial injury. Cell Mol Biol Lett. 2023;28(1):35. doi:10.1186/s11658-022-00415-8.

Durdagi G, Yildiz Pehlivan D, Oz Oyar E, Akyol Bahceci S, Ozbek M. Effects of melatonin and adrenomedullin in reducing the cardiotoxic effects of doxorubicin in rats. Cardiovasc Toxicol. 2021;21(5):354–364. doi:10.1007/s12012-020-09625-y.

Dziegiel P, Murawska-Cialowicz E, Jethon Z, et al. Melatonin stimulates the activity of protective antioxidative enzymes in myocardial cells of rats in the course of doxorubicin intoxication. J Pineal Res. 2003;35:183–187. doi:10.1034/j.1600-079X.2003.00079.x.

Huang X, Hou J, Huang S, et al. Melatonin ameliorates myocardial injury by reducing apoptosis and autophagy of cardiomyocytes in a rat cardiopulmonary bypass model. PeerJ. 2021;9:e11264. doi:10.7717/peerj.11264.

Jie L, Zhou T, Li G, et al. Melatonin promotes coronary angiogenesis and ameliorates cardiac dysfunction after myocardial infarction via endothelial LRRC8A. J Mol Cell Cardiol. 2026;217:228–237. doi:10.1016/j.yjmcc.2026.07.007.

Lazarević M, Kostić M, Džopalić T, et al. Melatonin mediates cardiac tissue damage under septic conditions induced by lipopolysaccharide. Int J Mol Sci. 2024;25(20):11088. doi:10.3390/ijms252011088.

Li HR, Wang C, Sun P, et al. Melatonin attenuates doxorubicin-induced cardiotoxicity through preservation of YAP expression. J Cell Mol Med. 2020;24:3634–3646. doi:10.1111/jcmm.15057.

Liu D, Ma Z, Di S, et al. AMPK/PGC1α activation by melatonin attenuates acute doxorubicin cardiotoxicity via alleviating mitochondrial oxidative damage and apoptosis. Free Radic Biol Med. 2018;129:59–72. doi:10.1016/j.freeradbiomed.2018.08.032. Corrigendum: Free Radic Biol Med. 2024;217:190. doi:10.1016/j.freeradbiomed.2024.03.013.

Liu F, Zhong A, Li J, et al. Melatonin alleviates diabetic cardiomyopathy by inhibiting cellular senescence via activation of the MT2/SIRT1/Nrf2 signaling pathway. J Pineal Res. 2026;78(5):e70185. doi:10.1111/jpi.70185.

Liu X, Chen Z, Chua CC, et al. Melatonin as an effective protector against doxorubicin-induced cardiotoxicity. Am J Physiol Heart Circ Physiol. 2002;283(1):H254–H263. doi:10.1152/ajpheart.01023.2001.

Luo R, Yang Z, Liang W, et al. Diurnal variation in melatonin-mediated cardiac protection via Per2 expression in heart. J Pineal Res. 2025;77(2):e70036. doi:10.1111/jpi.70036.

Mao ZJ, Lin H, Xiao FY. Melatonin against myocardial ischemia-reperfusion injury: a meta-analysis and mechanism insight from animal studies. Oxid Med Cell Longev. 2020;2020:1241065. doi:10.1155/2020/1241065.

Mousavinia SM, Larti F, Ranjbar H, et al. Evaluating the cardioprotective effects of melatonin in non-metastatic breast cancer patients receiving doxorubicin plus cyclophosphamide: a triple-blind, placebo-controlled randomized controlled trial. Iran J Pharm Res. 2025;24(1):e162962. doi:10.5812/ijpr-162962.

Othman AI, El-Missiry MA, Amer MA, Arafa M. Melatonin controls oxidative stress and modulates iron, ferritin, and transferrin levels in adriamycin treated rats. Life Sci. 2008;83:563–568. doi:10.1016/j.lfs.2008.08.004.

Öz E, Erbaş D, Sürücü HS, Düzgün E. Prevention of doxorubicin-induced cardiotoxicity by melatonin. Mol Cell Biochem. 2006;282:31–37. doi:10.1007/s11010-006-1153-9.

Pehlivan DY, et al. The effects of melatonin and thymoquinone on doxorubicin-induced cardiotoxicity in rats. Bratisl Lek Listy. 2020;121(10):753–759. doi:10.4149/BLL_2020_123.

Prestes JP, de Oliveira VR, Zimmer A, et al. Cardioprotective effects of melatonin in vitro and in two in vivo models of heart disease: isoproterenol-induced cardiac injury and pulmonary hypertension. Toxicol Appl Pharmacol. 2026:118038. doi:10.1016/j.taap.2026.118038.

Sahna E, Parlakpinar H, Ozer MK, Ozturk F, Ozugurlu F, Acet A. Melatonin protects against myocardial doxorubicin toxicity in rats: role of physiological concentrations. J Pineal Res. 2003;35(4):257–261. doi:10.1034/j.1600-079X.2003.00084.x.

Shi W, Qin J, Lin J, et al. Melatonin attenuates post-resuscitation myocardial dysfunction with associated improvements in mitochondrial dynamics in rats. Eur J Med Res. 2026. doi:10.1186/s40001-026-05149-3.

Sun X, Sun P, Zhen D, et al. Melatonin alleviates doxorubicin-induced mitochondrial oxidative damage and ferroptosis in cardiomyocytes by regulating YAP expression. Toxicol Appl Pharmacol. 2022;437:115902. doi:10.1016/j.taap.2022.115902.

Wang P, Wang D, Lv Z, et al. Melatonin inhibits ferroptosis in myocardial ischemia/reperfusion injury by inhibiting the ATM/p53 signaling pathway. Redox Rep. 2025;30(1):2583802. doi:10.1080/13510002.2025.2583802.

Xu MF, Ho S, Qian ZM, Tang PL. Melatonin protects against cardiac toxicity of doxorubicin in rat. J Pineal Res. 2001;31(4):301–307. doi:10.1034/j.1600-079X.2001.310403.x.

Yang G, Song M, Hoang DH, et al. Melatonin prevents doxorubicin-induced cardiotoxicity through suppression of AMPKα2-dependent mitochondrial damage. Exp Mol Med. 2020;52:2055–2068. doi:10.1038/s12276-020-00541-3.

Zhang W, Wang X, Tang Y, Huang C. Melatonin alleviates doxorubicin-induced cardiotoxicity via inhibiting oxidative stress, pyroptosis and apoptosis by activating Sirt1/Nrf2 pathway. Biomed Pharmacother. 2023;162:114591. doi:10.1016/j.biopha.2023.114591.

Zhang Y, et al. Protective effect of melatonin against Adriamycin-induced cardiotoxicity. Exp Ther Med. 2013;5(5):1496–1500. doi:10.3892/etm.2013.989.

Zhuo X, Jiang H. Protective effects of melatonin in cisplatin-induced cardiac toxicity: possible role of BDNF-TNF-α signaling pathway. Acta Cir Bras. 2022;37(2):e370208. doi:10.1590/acb370208.

Downloads

Published

2026-10-31

Issue

Section

Articles

How to Cite

MELATONIN-MEDIATED CARDIOPROTECTION ACROSS EXPERIMENTAL MODELS OF CARDIAC INJURY: A CRITICAL NARRATIVE REVIEW WITH PRIMARY-SOURCE QUANTITATIVE COMPARISONS. (2026). ISIR Journal of Business and Management Studies (ISIRJBMS), 3(5), 21-35. https://isirpublisher.com/index.php/isirjbms/article/view/44

Most read articles by the same author(s)

Similar Articles

11-20 of 46

You may also start an advanced similarity search for this article.